Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood thinner plus progesterone prevent recurrent miscarriages?

NCT ID NCT07796737

Disease control Sponsor: General University Hospital, Prague Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding enoxaparin, a blood thinner, to standard progesterone treatment increases the chance of a live birth in women who have had two or more unexplained miscarriages. Participants receive either progesterone alone or progesterone plus daily enoxaparin injections. The study tracks live birth rates and pregnancy complications to see if the combination helps more women carry a baby to term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of vaginal micronized progesterone and enoxaparin (a low molecular weight heparin)
What this could lead to
If it works, this combination could offer a new treatment to help women with unexplained recurrent miscarriages carry a baby to term.
What could go wrong
The trial is still testing the idea, and adding enoxaparin carries a risk of bleeding. It may not improve live birth rates beyond progesterone alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 264 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of ≥2 consecutive unexplained miscarriages before 20 weeks of gestation. * Confirmed intrauterine pregnancy by ultrasound and/or serum β-hCG (≥5 weeks). * Willingness to follow study procedures (progesterone use, possible daily - injections) and provide written informed consent. * No medical contraindication to progesterone or LMWH. Exclusion Criteria: * Documented antiphospholipid syndrome or any current anticoagulant requirement. * Anatomical abnormalities (e.g., significant uterine malformations, large fibroids) conclusively linked to RPL. * Known hypersensitivity to enoxaparine or heparins, or prior heparin-induced thrombocytopenia (HIT). * Use of systemic steroids (beyond standard pregnancy doses) for other immunological or inflammatory conditions. * Severe renal insufficiency (eGFR \<30 mL/min), advanced liver disease, or other clinically significant systemic autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis) that may affect pregnancy or study compliance. * Inability or unwillingness to comply with study requirements (language barriers, severe psychiatric conditions, etc.). * Abnormal karyotype

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnancy loss are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Abortion, Spontaneous habitual spontaneous abortion pregnancy disorder with abortive outcome pregnancy loss, recurrent, susceptibility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnancy loss Pregnancy loss, early

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General University Hospital in Prague

    Prague, 12800, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.